Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Sells $70,777.20 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley sold 10,470 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $70,777.20. Following the completion of the sale, the senior vice president now directly owns 378,245 shares of the company’s stock, valued at approximately $2,556,936.20. This represents a 2.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Abeona Therapeutics Stock Up 4.0%

Shares of ABEO stock opened at $6.74 on Monday. Abeona Therapeutics Inc has a fifty-two week low of $3.93 and a fifty-two week high of $7.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a market capitalization of $344.80 million, a PE ratio of -2.51 and a beta of 1.54. The stock’s 50-day simple moving average is $5.56 and its 200-day simple moving average is $5.57.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.11. Equities analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors have recently modified their holdings of the company. Twinbeech Capital LP purchased a new position in Abeona Therapeutics in the fourth quarter valued at $58,000. Squarepoint Ops LLC acquired a new position in Abeona Therapeutics during the 4th quarter worth approximately $67,000. Cannon Global Investment Management LLC acquired a new position in Abeona Therapeutics during the 1st quarter worth approximately $67,000. Oxford Asset Management LLP purchased a new stake in shares of Abeona Therapeutics during the 4th quarter worth approximately $118,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $190,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on ABEO. Stifel Nicolaus decreased their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Alliance Global Partners reissued a “buy” rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. HC Wainwright boosted their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, April 30th. Finally, Oppenheimer started coverage on Abeona Therapeutics in a report on Monday, June 2nd. They issued an “outperform” rating and a $19.00 target price for the company. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Abeona Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.25.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.